Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis

Kišš, Igor; Kuhn, Matyáš; Hrusak, Kristian; Buchler, Benjamin; Boublíková, Ludmila; Büchler, Tomáš

doi:10.3389/fonc.2022.946307

Cited by 6 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon diagnosis, the reduced sleep duration was connected to poor sleep quality, and insomnia was the most common sleep disturbance observed in these lung cancer patients, with a major impact on their quality of life. In contrast to our study, in previous studies that investigated immunotherapy, insomnia remained even in patients who exhibited a partial response or a complete response [ 27 ]. Moreover, the sleep disturbance symptoms in these studies were indifferent to the PD-L1 expression status.…”

Section: Discussioncontrasting

confidence: 99%

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival

et al. 2023

View full text Add to dashboard Cite

Introduction: Non-small-cell lung cancer is still diagnosed at an inoperable stage and systematic treatment is the only option. Immunotherapy is currently considered to be the tip of the arrow as the first-line treatment for patients with a programmed death-ligand 1 ≥ 50. Sleep is known to be an essential part of our everyday life. Patients and Methods: We investigated, upon diagnosis and after nine months, 49 non-small-cell lung cancer patients undergoing immunotherapy treatment with nivolumab and pemprolisumab. A polysomnographic examination was conducted. Moreover, the patients completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Severity Scale (FSS) and the Medical Research Council (MRC) dyspnea scale. Results: Tukey mean-difference plots, summary statistics, and the results of paired t-test of five questionnaire responses in accordance with the PD-L1 test across groups were examined. The results indicated that, upon diagnosis, patients had sleep disturbances which were not associated with brain metastases or their PD-L1 expression status. However, the PD-L1 status and disease control were strongly associated, since a PD-L1 ≥80 improved the disease status within the first 4 months. All data from the sleep questionnaires and polysomnography reports indicated that the majority of patients with a partial response and complete response had their initial sleep disturbances improved. There was no connection between nivolumab or pembrolisumab and sleep disturbances. Conclusion: Upon diagnosis, lung cancer patients have sleep disorders such as anxiety, early morning wakening, late sleep onset, prolonged nocturnal waking periods, daytime sleepiness, and unrefreshing sleep. However, these symptoms tend to improve very quickly for patients with a PD-L1 expression ≥80, because disease status improves also very quickly within the first 4 months of treatment.

show abstract

Section: Discussioncontrasting

confidence: 99%

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In the data collection of our study as well as in the literature, the various primary oncological pathologies of the selected sample were examined [ 23 , 34 , 39 , 41 , 42 ]. In the selected scientific studies, it is claimed that based on the type of tumor, a different load of symptoms depends, as well as a variation in the quality of sleep, in particular in patients with lung cancer due to the presence of respiratory problems [ 41 , 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Self-Completion Questionnaire on Sleep Evaluation in Patients Undergoing Oxaliplatin Therapy: An Observational Study

Mussa,

Allegra,

Armando

et al. 2024

Cancers

View full text Add to dashboard Cite

Sleep is a fundamental human need; sleep disruption, in fact, causes an increase in the activity of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, metabolic effects, changes in circadian rhythms, and pro-inflammatory responses. The scientific literature is finally starting to pay attention to the central role of sleep alterations in patients health. Oxaliplatin is extensively used for the treatment of gastrointestinal cancer and other malignancies, with an increased frequency of use in recent years. This study aims to understand the effects of sleep complaints on health and quality of life in cancer patients treated with oxaliplatin. A study has been conducted through the creation and distribution of questionnaires to patients to investigate their complaints about sleep quality. We observed significant differences between males and females in evaluating sleep hygiene scores, the Pittsburgh Sleep Quality Index, and previous difficulty sleeping. Moreover, in females, stress, worries, and anxiety seem to play a negative role in the sleep hygiene score. The obtained results could improve the interest of healthcare personnel and caregivers in sleep quality in patients undergoing chemotherapy.

show abstract

“…The methodology for selecting studies is depicted in Fig. 1 and was similar to one used in our previous systematic analyses [6,7]. Criteria for inclusion were restricted to phase 3 clinical trials that included detailed tables of adverse events within the ClinicalTrials.gov repository.…”

Section: Search Strategymentioning

confidence: 99%

Pruritus and xerodermia in patients treated with checkpoint inhibitors for melanoma, lung and renal cancer: a meta-analysis

Kiss,

Svoboda,

Horska

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Dermatologic adverse events (DAEs) are common in patients treated with immune checkpoint inhibitors (ICI) for cancer. Objective: To evaluate the incidence of two selected dermatologic adverse events (DAEs), pruritus and xerodermia, reported as adverse events in phase 3 randomised clinical trials using ICI in patients with lung cancer, renal cancer, and melanoma. Methods: Phase 3 studies where treatment included an ICI in the experimental arm were analysed. For pruritus, 42 studies were analysed with a total of 29,502 evaluable patients. For xerodermia, the number of studies was 23 with 17,341 patients. Results:. Pruritus was associated with ICI therapy with OR of 3.02 (95% CI 2.57–3.55). Compared to renal cell carcinoma (RCC) treated with anti-programmed death (PD-1) agents, patients with melanoma had higher odds of reporting pruritus, reaching statistical significance for the anti-PD-1 and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) treatment. Patient with lung cancer had significantly lower odds of pruritus across all ICI types compared to other analysed tumour types. Xerodermia was also associated with ICI treatment. Using RCC/PD-1 as a reference, there was a trend to higher incidence of xerodermia in patients with melanoma. Patients with lung cancer had significantly lower odds of xerodermia regardless of ICI type. Conclusion: The present systematic analysis indicates that pruritus and xerodermia are associated with ICI treatment of any type compared to non-immunologic therapies. There appears to be a higher incidence of these DAEs in patients with melanoma and RCC compared to patients with lung cancer.

show abstract

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis

Cited by 6 publications

References 99 publications

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival

Self-Completion Questionnaire on Sleep Evaluation in Patients Undergoing Oxaliplatin Therapy: An Observational Study

Pruritus and xerodermia in patients treated with checkpoint inhibitors for melanoma, lung and renal cancer: a meta-analysis

Contact Info

Product

Resources

About